Erin O’Boyle joined Rezolute in 2019 with nearly 20 years of operational and management experience across all phases of development covering several therapeutic areas, including oncology, anemia, idiopathic pulmonary fibrosis, and rare disease indications. Prior to joining Rezolute, Erin worked at Fibrogen where she led all clinical outsourcing and governance activities. She successfully contracted and managed all vendors for each clinical department which supported their various programs ranging from a rare orphan pediatric study to global Phase 3 development.

Before transitioning to a clinical lead in both contracting and governance, Erin was the Head of Clinical Operations at Heron Therapeutics. During her time at Heron Therapeutics, she successfully led a clinical program from Phase 1 up through NDA approval of SUSTOL^® (granisetron), an extended-release injection, for subcutaneous use for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy. To date, this is the largest CINV program ever conducted.

Erin obtained a Bachelor’s degree in Biology from Stonehill College.